SEC Filing Timeline
8-KSep 08, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KSep 04, 2026
Material agreement · Items 1.01,2.03,7.01,9.01
10-QAug 06, 2026
Quarterly report
8-KAug 06, 2026
Earnings release · Items 2.02,9.01
8-KJun 15, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KJun 10, 2026
Shareholder vote results · Items 5.07
10-QMay 11, 2026
Quarterly report
8-KMay 11, 2026
Earnings release · Items 2.02,9.01
8-KApr 30, 2026
Material agreement · Items 1.01,2.02,9.01
DEFA14AApr 30, 2026
Additional proxy
DEF 14AApr 30, 2026
Proxy statement
424B5Apr 29, 2026
Prospectus / offering
424B5Apr 27, 2026
Prospectus / offering
8-KApr 27, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KApr 10, 2026
Charter/bylaws amendment · Items 5.03,9.01
Recent News (Finnhub)
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
3 Promising Genomics Stocks in the Spotlight in 2026
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTL…